Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05363605 · ClinicalTrials.gov registry record · Phase 1
A Study of [225Ac]-FPI-1966 in Participants With Advanced Solid Tumours
A Phase 1 study, sponsored by Fusion Pharmaceuticals.
- Terminated
- Registry status
- Phase 1
- Development phase
- 6
- Enrollment target
NCT05363605 is a Phase 1 study that was terminated before completion, run by Fusion Pharmaceuticals. The registered enrollment target is 6 participants.
The verdict
NCT05363605, a Phase 1 study, was terminated before completion, sponsored by Fusion Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 6 participants
- Enrollment target
Study Summary
This first-in-human study evaluates safety, tolerability and distribution of \[225Ac\] FPI-1966, \[111In\]-FPI-1967, and vofatamab in patients with FGFR3-expressing solid tumors.
Interventions
- DRUG [225Ac]-FPI-1966
- DRUG [111In]-FPI-1967
- BIOLOGICAL vofatamab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2022-04-20 |
| Est. Completion | 2023-09-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05363605
The ClinicalTrials.gov registry entry for NCT05363605 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 6 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Fusion Pharmaceuticals, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which [225Ac]-FPI-1966 is the first listed.
NCT05363605 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05363605 about?
NCT05363605 is a clinical study titled "A Study of [225Ac]-FPI-1966 in Participants With Advanced Solid Tumours". This first-in-human study evaluates safety, tolerability and distribution of \[225Ac\] FPI-1966, \[111In\]-FPI-1967, and vofatamab in patients with FGFR3-expressing solid tumors.
What is the current status of trial NCT05363605?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 6 participants. The study started on 2022-04-20. Estimated completion is 2023-09-08.
What interventions are being tested in trial NCT05363605?
The interventions under investigation include: [225Ac]-FPI-1966 (DRUG), [111In]-FPI-1967 (DRUG), vofatamab (BIOLOGICAL).
Who is sponsoring clinical trial NCT05363605?
This trial is sponsored by Fusion Pharmaceuticals, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.